ClinicalTrials.gg

Program

JMKX003948

A development code. Also written as “JMKX003948 Ophthalmic Suspension”.

Its studies are mostly in Macular Degeneration · Carcinoma, Renal Cell, led by Jemincare.

Furthest: phase 1, since Mar 14, 20242 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare22 open or runningphase 1since Mar 14, 2024Mar 14, 2024none ahead

Also a collaborator on its studies: Zhejiang Hangyu Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2024First study: phase 1 study in Renal Cell Carcinoma MetastaticFirst studyNCT06321250 · 80 planned · China
  2. Dec 25, 2024Phase 1 study in Macular DegenerationNCT06832657 · 40 planned

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06832657Macular Degeneration1Not yet recruitingDec 202540
NCT06321250Renal Cell Carcinoma Metastatic · China1RecruitingMay 31, 202680

How it is read

Names in the registry

  • “JMKX003948 Ophthalmic Suspension”, 1 entry
  • “JMKX003948”, 1 entry

Codes read as this program: JMKX003948.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.